Arbaprostil's [15(R)-15-methyl PGE2] effects on intrauterine pressure in the nonpregnant and pregnant human female — A report of four clinical trials
| Autor: | H. Bogaerts, S. Leodolter, M.M. Kitt, D.R. Wood, M.D. Burns, A.R. Euler, J. Lookabaugh, T.D. Phan, J. Huber |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Prostaglandins E
Synthetic medicine.medical_specialty Dose Clinical Biochemistry Uterus Physiology Dinoprostone Arbaprostil Uterine Contraction Pregnancy medicine Humans Montevideo units Abortifacient Gynecology Clinical Trials as Topic Dose-Response Relationship Drug business.industry Cell Biology medicine.disease Pregnancy Trimester First medicine.anatomical_structure In utero Gestation Female business |
| Zdroj: | Prostaglandins, Leukotrienes and Essential Fatty Acids. 38:91-98 |
| ISSN: | 0952-3278 |
| DOI: | 10.1016/0952-3278(89)90091-4 |
| Popis: | Four clinical trials evaluating arbaprostil's effects on the human uterus are reported. The initial two trials measured intrauterine pressures in nonpregnant and pregnant human females following arbaprostil doses of 10, 25, and/or 50 mcg. No statistical differences were found at any dosage level in either study for average uterine resting pressures, average peak pressures, the number of contractions or Montevideo units. Subsequently, two trials determined the abortifacient potential of arbaprostil in pregnant women during the first trimester. The first utilized total daily doses of 400 and 800 mcgs. while the second used total daily doses of 1200 and 1600 mcgs. Vaginal spotting was noted in one woman receiving 400 mcgs, three receiving 1200 mcgs, and in two receiving 1600 mcgs. One episode of moderate bleeding was seen in the latter study. Based on these studies, arbaprostil exhibits little potential for inducing abortifacient activity at these dosages in these patient populations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|